US Attorney scrutinizes Copaxone marketing

Share this article:

The US Attorney's Office for the Southern District of New York is looking into how Teva marketed its MS drug Copaxone and Parkinson's medication Azilect since 2006. The Associated Press reports that the drugmaker announced the investigation Monday and is exploring “possible violations of the False Claims Act.” Citi research analyst Liav Abraham told the AP that the FDA has increased its False Claims investigations over the past few years and that they can take several years to wrap.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters